Search Results

13 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 00

    New Approach Methods (NAMs) Symposium-II: Applications in Tobacco Regulatory Sciences

    LEE K.M.(1); SIMMS L.(2)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    New Approach Methods (NAMs) in toxicology refer generally to in vitro and in silico or computational methodologies that, without additional in vivo animal testing, could enable clinically relevant toxicological risk assessment. At CORESTA...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, NAM 03

    Exposure to fresh whole smoke and aerosols: standard and novel (3D) in vitro models

    POUR S.J.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Brands PLC, Bristol, U.K.
    New Approach Methods (NAMs) describe non-animal- based methodologies that enable more human relevant toxicological risk assessments. In this talk, regulatory in vitro toxicology assays (CORESTA battery) are refined for NGP (Next Generation Product)...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 27

    Next generation product aerosol bubbled extracts show little to no effect in high content screening endpoints when compared to cigarette smoke bubbled extracts

    TRELLES STICKEN E.(1); WIECZOREK R.(1); BODE L.M.(1); SIMMS L.(2); STEVENSON M.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), BioToxLab, Hamburg, Germany; (2) Imperial Tobacco Limited, In vitro Research, Bristol, U.K.
    Tobacco-based and tobacco-free next generation products (NGPs) are understood to be a less harmful alternative to conventional combustible cigarettes. The objective of this study was to compare the in vitro biological response of cigarette smoke...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 33

    Quantitative risk assessment (QRA) indicates reduced risk potential for carcinogenic and non-carcinogenic effects of the aerosol of the next generation products (NGPs) compared to reference cigarettes

    AYALA-FIERRO F.(1); CZEKALA L.(2); SIMMS L.(2); RUDD K.(2); CAVA G.(2); STEVENSON M.(2)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    In order to understand the potential relative health risks of NGPs compared to cigarettes, we compared the relative risks of aerosols from tobacco-containing and tobacco-free NGPs to the smoke generated from a reference cigarette. Quantitative Risk...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 34

    Next generation product aerosols induce lower biological activity than combusted cigarettes: a comparison of in vitro cell migration in the scratch wound assay

    RUDD K.(1); BUDDE J.(2); TRELLES STICKEN E.(2); WIECZOREK R.(2); SIMMS L.(1); STEVENSON M.(1)
    (1) Imperial Brands PLC, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany
    Smoking combustible cigarettes is a cause of serious diseases in smokers, including heart disease. There are many commercially available next generation products (NGPs), such as tobacco-free e-vapour products, aiming to provide an alternative to...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 37

    Use of cell media nicotine concentration as a marker to predict cells surface deposited nicotine in transwells after fresh smoke/aerosol exposure

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS l.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    Exposure of organotypic 3D lung models at the air liquid interface (ALI) to fresh whole smoke/aerosol provides a more human relevant exposure assessment of combustible cigarettes and e-vapour products. The aim of this study is to present a method...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 01

    The application of in vitro Toxicity Testing in 21 Century (TT21C) for next generation products

    SIMMS L.(1); TRELLES STICKEN E.(2)
    (1) Imperial Brands PLC, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany
    The aim is to demonstrate the feasibility of TT21C in vitro methods as part of an overall assessment framework for next generation products (NGP). TT21C methodologies can be used to assess harm reduction potential of NGPs using human-derived...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 22

    Dosimetry: TPM and nicotine delivery of combusted tobacco products to the 24 and 96 Multi Well Plate and inserts on Smoke Aerosol Exposure In Vitro System (SAEIVS)

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    In vitro exposure systems are key tools for the risk assessment of emerging electronic nicotine delivery systems as well as for conventional tobacco products. The Smoke Aerosol Exposure in vitro System (SAEIVS) used at Imperial Tobacco Limited is...